PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjLink to Publisher's site
 
BMJ. 1999 December 11; 319(7224): 1534–1539.
PMCID: PMC28296

Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks

Michael Philipp, professor of psychiatry,a Ralf Kohnen, professor of psychology,b and Karl-O Hiller, senior research fellowc

Abstract

Objectives

To assess the efficacy and safety of hypericum extract (STEI 300, Steiner Arzneimittel, Berlin) compared with imipramine and placebo in patients in primary care with a current episode of moderate depression.

Design

Randomised, double blind, multicentre, parallel group trial for 8 weeks.

Setting

Trained panel of 18 general practitioners from four German states: Bavaria, Berlin, Rhineland Palatinate, and Saxony.

Participants

263 patients (66 men, 197 women) with moderate depression according to ICD-10 (international classification of diseases, 10th revision) codes F32.1 and F33.1.

Interventions

1050 mg hypericum extract (350 mg three times daily), 100 mg imipramine (50 mg, 25 mg, and 25 mg daily), or placebo three times daily.

Main outcome measures

Change from baseline score on the 17 item version of the Hamilton depression scale, the Hamilton anxiety scale, the clinical global impressions scale, Zung's self rating depression scale, and SF-36, and adverse events profile.

Results

Hypericum extract was more effective at reducing Hamilton depression scores than placebo and as effective as imipramine (mean −15.4 (SD 8.1), −12.1 (7.4), and –14.2 (7.3) respectively). Comparable results were found for Hamilton anxiety and clinical global impressions scales and were most pronounced for the Zung self rating depression scale. Quality of life was more improved in the standardised mental component scale of the SF-36 with both active treatments than with placebo but in the physical component scale was improved only by hypericum extract compared with placebo. The rate of adverse events with hypericum extract was in the range of the placebo group but lower than that of the imipramine group (0.5, 0.6, and 1.2 events per patient respectively).

Conclusions

At an average dose of 350 mg three times daily hypericum extract was more effective than placebo and at least as effective as 100 mg imipramine daily in the treatment of moderate depression. Treatment with hypericum extract is safe and improves quality of life.

Key messages

  • Hypericum extract (STEI 300) was effective after 4, 6, and 8 weeks of treatment in patients with moderate depression
  • Simultaneous analysis confirmed hypericum extract to be at least as efficacious as imipramine 100 mg daily after eight weeks of treatment
  • Besides better antidepressive efficacy both hypericum extract and imipramine improved quality of life
  • Patients tolerate hypericum extracts much better than they do tricyclics and therefore by improving patients' compliance hypericum extracts are promising drugs for long term treatment

Introduction

Depressive disorders are recognised as disabling psychiatric illnesses, with lifetime prevalences of over 10% in the general population.1 These conditions are underdiagnosed and frequently undertreated.2 The prevalence of depressive disorders in primary care in Germany has been estimated at 8.6%.3

A systematic review of 27 clinical studies of different hypericum preparations concluded that they are more effective than placebo in the treatment of mild to moderate depression.4 Previous research has, however, been criticised for methodological shortcomings particularly in equivalence trials with other antidepressants.5,6 Most comparative trials concluded that hypericum products were as effective as synthetic antidepressants, but the trials lacked a placebo group.4 We report the results of the first three arm study in which hypericum extract (STEI 300, Steiner Arzneimittel, Berlin) was compared with a tricyclic antidepressant and a placebo in the treatment of patients for eight weeks with moderate depression. We followed recent statistical requirements and recommendations.7

Methods

Our study was conducted according to the declaration of Helsinki and the European guidelines for good clinical practice.8 The study protocol was approved by four medical ethics committees in Germany.

Design, efficacy, and safety evaluation

We conducted a double blind, randomised, placebo controlled, multicentre trial for eight weeks. Patients were screened for one week before treatment, which included a washout period for previous antidepressants. Efficacy and safety were evaluatedafter 1, 2, 4, 6, and 8 weeks with the 17 item version of the Hamilton depression rating scale, the Hamilton anxiety scale, the clinical global impressions scale, and the Zung self rating depression scale. Data for evaluation of safety comprised adverse events, clinically relevant changes in ECG, measurements of vital signs, and physical examinations. Quality of life was rated by the patients with SF-36. All participant doctors were trained by the principal investigator (MP)to improve reliability in the rating of the main outcome criterion, the Hamilton depression total score. Blocks of 12 patients were randomised in the ratio 5:5:2 for hypericum extract STEI 300, imipramine, and placebo respectively.

Patients

Patients were continuously selected from the cohorts of depressed patients by a panel of 18 general practitioners. Box BoxB1B1 summarises the main inclusion and exclusion criteria.

: Main inclusion and exclusion criteria

Drugs

During the screening period patients remained untreated until a baseline evaluation of efficacy and safety was completed. All patients were treated with three capsules of trial drug daily. Hypericum extract STEI 300 (extracted from St John's wort with 60% ethanol w/w; composition of pharmaceutically relevant substances 0.2%-0.3% hypericin and pseudohypericin and 2%-3% hyperforin according to high performance liquid chromatography) was given in a constant dose of 350 mg per capsule (total daily dose 1050 mg). Imipramine was titrated in a dose of 50 mg on the first treatment day, 75 mg on days 2-4, and 100 mg (50 mg, 25 mg, and 25 mg) thereafter. The capsules were identical in appearance and taste and were packed in identical containers identified only by patient number. Compliance with drug intake (80%-120% of the prescribed dose per protocol) was checked by counting pills during and at the end of the treatment period.

Statistical analysis

Changes in scores on the Hamilton depression rating scale between baseline and final assessment of efficacy were defined in the study protocol as primary efficacy criterion. The definitions of endpoints for confirmative testing (six weeks for comparison with placebo, eight weeks for comparison with imipramine) are based on the recommendations for evaluating antidepressive efficacy.9 Three hypotheses were tested in a hierarchical procedure: superiority of hypericum extract over placebo, equivalence between hypericum extract and imipramine, and superiority of active control over placebo. Confirmatory hypothesis testing was to be stopped if the first or second null hypothesis could not be rejected (P[less-than-or-eq, slant]0.025, one sided test problem). Multiple two sample t tests were used for statistical hypothesis testing. Two sided 95% confidence intervals, including centres as stratum,10 were calculated for comparisons between the treatments in this trial.

All other scales were analysed as secondary efficacy criteria with two sample tests (t test, χ2 test) and interpreted on an exploratory basis. The evaluation of efficacy was based on the intention to treat analysis, using the method of last observation carried forward in the case of patients who prematurely dropped out of the study. Safety analysis included all patients who received at least one dose of any test drug and had safety assessments after baseline. The qualification of patients for the different analyses populations was defined in a blind review evaluation before unblinding the random code. Statistical analyses were performed with sas version 6.12.

Results

Patients

Overall, 263 patients were randomised in 18 centres (median 12 patients, 3 to 24 per centre) from October 1996 to April 1998 (see website). In the intention to treat population of 251 patients—hypericum extract (100 patients), imipramine (105), and placebo (46)—the three treatment groups were comparable for sex, age, height, weight, diagnoses according to the ICD-10, and scores on the initial Hamilton depression and Hamilton anxiety scales (table (table11).

Table 1
Characteristics of patients with moderate depressive episodes (safety population n=263) and baseline values in efficacy criteria (intention to treat population n=251). Values are means (SDs) unless stated otherwise

Compliance and efficicay

Overall compliance was satisfactory—on average patients took a mean 100% (4%) of their pills (range 69%-108%). Figure Figure11 shows the increasingly larger improvements at any assessment after baseline (with initial Hamilton depression total scores of 22 and 23 points on average) for hypericum extract and imipramine compared with placebo, with the largest improvement with hypericum extract. The placebo group also showed considerable improvements during the study.

Figure 1
Mean (SEM) change from baseline in Hamilton depression total scores at all visits in intention to treat population. Observed cases analysis at weeks 1, 2, and 4, and last observation carried forward analysis for weeks 6 and 8

The primary endpoint analysis showed that hypericum extract was more effective than placebo after six weeks of treatment (change from baseline −3.1, −5.4 to −1.5, negative values indicate better efficacy of hypericum extract; table table2).2). In the second hypothesis test, equivalent efficacy was shown between hypericum extract and imipramine (−1.2, 95% confidence interval −2.6 to 0.6). For imipramine we found only a strong tendency towards it being more effective than placebo after six weeks of treatment (−1.7, −3.89 to −0.05). However, the 95% confidence interval did not include the zero point of equal efficacy. The differences between the two treatment groups and placebo were comparable at week 8, but slightly less pronounced than in week 6 owing to further improvement in the placebo group.

Table 2
Changes from baseline in intention to treat population for evaluation of efficacy. Values are means (SDs) unless stated otherwise

In the Hamilton anxiety scale, improvements were greater after six weeks of treatment with hypericum extract than with placebo (−2.7, −5.44 to −0.51) and less pronounced in the imipramine group (−1.8, −4.43 to 0.46). Compared with placebo (50%), the number of patients who improved in the clinical global impressions scale was noticeably higher under active treatments: 74% in the hypericum group (24%, 13% to 39%), 71% in the imipramine group (21%, 9% to 35%). Differences between the active treatment groups and the placebo group were smaller at week 8 (table (table22).

In the Zung self rating depression scale both treatments were superior to placebo at week 6 and hypericum extract was also more efficacious at week 8, showing a higher sensitivity for active control versus placebo (fig (fig2,2, table table22).

Figure 2
Mean (SEM) change from baseline in Zung self rating depression total score at all visits in intention to treat population. Observed cases analysis for weeks 1, 2, and 4, and last observation carried forward analysis for weeks 6 and 8

Quality of life

The standardised component scales of the SF-36 are reported in this paper as a summary information on quality of life. The differences between both drugs compared with placebo were larger in the mental component scale than in the physical component scale. In both scales hypericum extract was more effective than placebo (mental component 5.3, 1.9 to 8.7, physical component 3.5, 1.1 to 6.1); a positive value indicates better efficacy of hypericum extract (table (table22).

Safety

In the safety population, 22% (0.5 events per patient) of the hypericum group and 46% (1.2) of the imipramine group reported adverse events with treatment (table (table3);3); the placebo group (19%) was comparable to that of the hypericum group (0.6). Overall, the most frequent adverse event was dry mouth (38% in the imipramine group). The most frequently reported adverse event in the hypericum group was nausea (8%, 3.3% to 14.3%). No serious adverse events were reported in the hypericum and imipramine groups. One patient in the placebo group attempted suicide but did eventually complete the study although with little progress.

Table 3
Spontaneously reported or observed adverse events with total relative frequency >3% and with probable or possible relation to trial drug and dropout rate due to adverse events (safety population). Values are numbers (percentages)

Discussion

Efficacy of hypericum extract

Our results showed that hypericum extract STEI 300 was more effective than placebo after six weeks (confirmatory testing) and eight weeks (exploratory testing) of treatment in primary care patients with moderate depression. Our study sample was representive of some confounding demographic variables and disease characteristics in patients in primary care with depressive disorders, for example, age and sex distribution, severity, chronicity. According to Montgomery, a difference of more than three points in change from baseline on the Hamilton depression scale between both treatments is not only statistically but also clinically relevant.11 Following current recommendations for equivalence trials,12 we showed that hypericum extract was equivalent in efficacy to imipramine after eight weeks of treatment.

Efficacy of imipramine and placebo effects

Although the improvement in the imipramine group was considerable (63% and 67% on the Hamilton depression scale at weeks 6 and 8), indicating effective responder rates for antidepressive treatment, only a strong tendency towards superior efficacy over placebo could be found in the Hamilton depression scale. In our trial the dosage of 100 mg imipramine was a compromise between recommended mean dosage for efficacy13 and expected rate of adverse events. The participating doctors would not have accepted higher doses for the treatment of moderate depression owing to the expectation of frequent and severe side effects with consequences for compliance (increased drop out rates from the study) in this patient population. The 17 item version of the Hamilton depression scale has an inherent bias against tricyclics compared with both placebo and hypericum as it includes anticholinergic and other side effects in item 11 (“somatic anxiety”). Superiority of imipramine over placebo could be shown more clearly if this item was not included in the Hamilton depression total score (table (table2).2). Whether this methodological bias or a suboptimal dosage of imipramine led to the less pronounced difference between drug and placebo in the Hamilton score cannot be answered conclusively.A recent meta-analysis of dose effect relations in 33 studies with imipramine14 showed no increased efficacy above 100-200 mg imipramine but a superior efficacy compared with doses below 100 mg. Although the rate of anticholinergic adverse events was in the range expected for tricyclics unblinding was not a major shortcoming in this study as only 39% of imipramine treatments (hypericum extract 50%, placebo 26%) were correctly predicted by the investigators in this study in a retrospective assessment (data not shown).

Although modern antidepressants, such as selective serotonin reuptake inhibitors, are more suitable for comparison with hypericum because of their lower frequency of side effects, we chose imipramine mainly because tricyclics are still the most frequently prescribed antidepressants in primary care in Germany. This is because they cost less than modern antidepressants.

The rather high placebo response rate of 47% on the Hamilton depression scale after six weeks of treatment is within the known range for studies with hypericum extracts (0% to 56%)4 and with synthetic antidepressants (0% to 70%).15 Besides other factors (fluctuation of disease pattern, intense supervision according to the study setting), it may be either a result of a possible selection process of patients with a good prognosis in placebo controlled trials of hypericum or methodologically biased by the smaller size of the placebo group, which resulted in a maximum of four patients compared with 20 on active drugs per centre.

Quality of life and aspects of tolerability

Quality of life ratings with SF-36 were not included in clinical trials with hypericum extract and, with one exception,16 were not sensitive for differences between drug and placebo. We found differences to be largest in the mental component scale, but only hypericum extract was superior to placebo in the physical component scale. The higher rate of adverse events in the imipramine group is probably responsible for a lesser improvement in the physical component compared with the mental component.

Tolerability analysis showed a higher rate of adverse events in the imipramine group than in the other two treatment groups, which was primarily due to dry mouth. Generally, the observed favourable safety profile of hypericum extract agrees with the data from a recently published review.17

Conclusions

Since hypericum products may vary considerably in composition (total hypericins, hyperforin, flavonol derivatives) the results cannot be generalised to other extracts. Furthermore, the tested daily dosage of 1050 mg extract, which is equivalent to 6 g of the crude herb, is higher than that recommended and mostly used for the treatment of mild depression. In the first three arm comparative trial of hypericum extract, we showed that at an average dose of 350 mg three times daily hypericum extract STEI 300 was a more effective antidepressant than placebo and at least equally effective to 100 mg imipramine daily in the treatment of moderate depression. Also, any side effects with hypericum extract did not impair important quality of life measures. Since many depressed patients receive either no treatment or inadequate treatment after an initial depressive episode and are at increased risk of recurrence of such episodes,18 hypericum extract may thus be considered as an alternative first choice treatment in most cases of mild to moderate depression without psychotic symptoms.

Acknowledgments

We thank the doctors who contributed to the study: H Carboni, E Homsy, P Sandow, E Schwittay, H Wiswedel, D Breitfelder, M Oelker, A Berger, K D Bergert, H Hauer, A Naumburger, E Mandrella, R Krone, W Englisch, P Unterberg, H Leykauf, J Blasy, and M Staudinger.

Footnotes

Funding: Steiner Arzneimittel, Berlin, Germany.

Competing interests: KOH is an employee of Steiner Arzneimittel. RK is head of a contract research organisation (IMEREM), which is engaged in several clinical trials with hypericum extract for different pharmaceutical companies.

References

1. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill; 1996. pp. 431–459.
2. Lépine JP, Gastpar M, Mendlewicz J, Tylee A.on behalf of the Depression Research in European Society Steering Committee. Depression in the community: the first pan-European study DEPRES (depression research in European society) Int Clin Psychopharmacol 1997. 1219–29.29 [PubMed]
3. Linden M, Maier W, Achberger M, Herr R, Helmchen H, Benkert O. Psychiatric diseases and their treatment in general practice in Germany. Results of a World Health Organization (WHO) study. Nervenarzt. 1996;67:205–215. [PubMed]
4. Linde K, Mulrow CD. Cochrane Collaboration, editors. Cochrane Library. Issue 2. Oxford: Update Software; 1999. St John's wort for depression.
5. De Smet PAGM, Nolen WA. St John's wort as an antidepressant. BMJ. 1996;313:241–242. [PMC free article] [PubMed]
6. Volz HP. Controlled clinical trials of hypericum extracts in depressed patients—an overview. Pharmacopsychiat. 1997;30(suppl):72–76. [PubMed]
7. The European Commission. Adapted guideline from ICH-E9: note for guidance on statistical priniciples for clinical trials. London: European Agency for the Evaluation of Medicinal Products; 1998. [CPMP/ICH/363/96.].
8. The European Commission. Adapted guideline from ICH-E6: note for guidance on good clinical practice. London: European Agency for the Evaluation of Medicinal Products; 1997. [CPMP/ICH/135/95.].
9. The European Commission. Note for guidance: medicinal products for the treatment of depression. Brussels: Committee for Proprietary Medicinal Products; 1990.
10. Lehmacher W. Äquivalenznachweise bei Multicenter-Studien. In: Michaelis J, Hommel G, Wellek S, editors. Europäische Perspektiven der Medizinischen Informatik, Biometrie und Epidemiologie. Munich: MMV Medizin Verlag; 1993. pp. 152–154.
11. Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol. 1994;4:283–284.
12. Röhmel J. Therapeutic equivalence investigations: statistical considerations. Statist Med. 1998;17:1703–1714. [PubMed]
13. German Commission A. Monograph imipramine. Bundesanzeiger 1992, Aug 8.
14. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiat. 1999;174:297–303. [PubMed]
15. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry. 1992;53(suppl):5–18. [PubMed]
16. Heiligenstein JH, Ware JE, Jr, Beusterien KM, Roback PJ, Andrejasich C, Tollefson GD. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychogeriatr. 1995;7(suppl):125–137. [PubMed]
17. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St John's wort. Eur J Clin Pharmacol. 1998;54:589–594. [PubMed]
18. Angst J. A regular review of the long-term follow-up of depression. BMJ. 1997;315:1143–1146. [PMC free article] [PubMed]
1999 December 11; 319(7224): 1534–1539.

Commentary: Has hypericum found its place in antidepressant treatment?

Klaus Linde, senior researcher1-1001 and Michael Berner, clinical psychiatrist1-1002

Hypericum extracts are the most widely prescribed antidepressants in Germany and their popularity in other countries is increasing. The study of Philipp et al as well as other new trials1-1,1-2 confirm the existing evidence1-3 that such extracts are more effective than placebo in mild and moderately severe depression. The most relevant questions for clinical research are now whether hypericum is really as effective as standard antidepressants, whether it is effective and safe for long term treatment and for more severe forms of depression, and how different extracts and dosages compare.

The trial of Philipp et al is a relevant contribution to the first of these questions but also highlights some of the common problems in research on hypericum extracts. Existing trials have been criticised for comparing hypericum with low doses of standard antidepressants. This criticism also applies to some extent to this trial. The authors argue that higher doses would not have been accepted by the participating practitioners owing to the high rate of expected side effects. The comparison with the placebo control group shows that both treatments had specific effects. Nevertheless, the conclusion from this trial can only be that a comparatively high dose of the tested hypericum extract seems to be similarly effective as a comparatively low dose of imipramine.

The patients receiving the hypericum extract or placebo experienced less and different side effects than those taking imipramine. This might have caused some unblinding. It cannot be ruled out that this had some influence on the comparisons of imipramine versus placebo and imipramine versus hypericum. Unblinding is a possibly common but mostly undiscussed issue in many clinical studies. In our opinion, testing for unblinding should become routine in clinical trials. Philipp et al conclude from a retrospective assessment that unblinding was not a major shortcoming in their study, but without a more detailed description of how exactly this assessment was performed this statement cannot be substantiated by the reader. For a long time imipramine has been the gold standard for comparison in clinical trials of antidepressant treatment. Therefore, a comparison with imipramine is legitimate. But it would be important to know how hypericum extracts compare with selective serotonin reuptake inhibitors for both efficacy and side effects. So far there is only one trial comparing another hypericum extract with (the comparatively low dose of 20 mg) fluoxetine,1-4 which found similar effectiveness and rates of side effects in patients with mild to moderately severe depression. A large trial sponsored by the US National Center for Complementary and Alternative Medicine comparing hypericum, a selective serotonin reuptake inhibitor, and placebo in patients with major depression is ongoing.

The superiority of hypericum extract and imipramine over placebo is not very impressive in the trial by Philipp et al. However, the patients in the placebo group experienced considerable improvement, which seems plausible in moderately depressed patients in primary care. An interesting finding of the trial is also that hypericum extract seemed to have had a significant effect on quality of life.

In summary, this trial adds to the growing evidence on the effectiveness of hypericum in mildly and moderately depressed patients. Still, our personal differences on which treatment we would prefer in case we had a moderately severe depression indicates that the place of hypericum in antidepressant treatment is not yet fully established. Whereas one of us would prescribe a chemically defined antidepressant with a low side effect profile the other would first try hypericum.

Footnotes

 Competing interests: MB has received sponsorship from Schwabe in the past, manufacturer of a hypericum extract.

website extra: The sample size calculation and a chart showing the flow of participants through the trial appear on the BMJ's website www.bmj.com

References

1-1. Schrader E, Meier B, Brattström A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol. 1998;13:163–169.
1-2. Laakmann G, Dienel A, Kieser M. Clinical significance of hyperforin for the efficacy of hypericum extracts on depressive disorders of different severities. Phytomedicine 1998-5:435-42. [PubMed]
1-3. Linde K, Mulrow CD. St John's wort for depression. In Cochrane Collaboration. Cochrane Library. Issue 1. Oxford: Update Software, 1999.
1-4. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between St John's wort extract LoHyp-57 and fluoxetine. Arzneim-Forsch/Drug Res. 1999;49:289–296. [PubMed]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Group